| Pneumonia due to Pseudomonas aeruginosa: the levofloxacin clinical trials experience. | |
| | |
MedLine Citation:
|
PMID: 16709306 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Respiratory infections caused by Pseudomonas aeruginosa present significant treatment challenges, including that of overcoming intrinsic and adaptive resistance by these organisms. The fluoroquinolones may provide an effective option for treating these infections. In this analysis, we report on the efficacy of levofloxacin in the treatment of community-acquired pneumonia (CAP) and nosocomial pneumonia caused by P. aeruginosa using information from nine clinical studies supported by Johnson & Johnson Pharmaceutical Research and Development (Raritan, NJ) or Ortho-McNeil Pharmaceutical (Raritan, NJ). From these studies, a total of 36 patients were identified with pneumonia caused by P. aeruginosa and treated with levofloxacin (750 mg or 500 mg). For patients diagnosed with nosocomial pneumonia, levofloxacin treatment achieved a 64.7% (11/17) clinical success rate, compared with 41.2% (7/17) with comparator treatment (imipenem/cilastatin followed by ciprofloxacin) in the microbiologically evaluable population. Eradication rates were 58.8% with levofloxacin treatment vs. 29.4% with comparator (95% CI, -64.2 to 5.4). For levofloxacin-treated CAP patients with P. aeruginosa infections (n = 19), clinical success and microbiological eradication rates in the microbiologically evaluable population were 89.5% and 78.9%, respectively. Several limitations of this analysis exist including that this was a retrospective evaluation that pooled data from multiple studies with varying protocols, the number of patients included was limited, and the nosocomial pneumonia patients used adjunctive therapy with an antipseudomonal beta-lactam in most cases. Nonetheless, these findings suggest that levofloxacin may play a role in the treatment of these difficult respiratory infections. |
| | |
Authors:
|
Alan M Tennenberg; Neelam B Davis; Shu-Chen Wu; James Kahn |
Related Documents
:
|
1643936 - Igm anti-p1 immunoblotting. a standard for the rapid serologic diagnosis of mycoplasma ... 3235666 - Characteristics of anti-legionella antibodies in patients infected with legionella pneu... 7979856 - Microbiology of community-acquired bacterial pneumonia in persons with and at risk for ... 16416386 - Clinical features, aetiology and short-term outcome of interstitial pneumonitis in hiv/... 8871676 - Nonrheumatoid igm in human hepatitis c virus-associated type ii cryoglobulinemia recogn... 8648206 - Igg antibody to pneumococcal capsular polysaccharide in human immunodeficiency virus-in... |
Publication Detail:
|
Type: Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Current medical research and opinion Volume: 22 ISSN: 0300-7995 ISO Abbreviation: Curr Med Res Opin Publication Date: 2006 May |
Date Detail:
|
Created Date: 2006-05-19 Completed Date: 2006-09-22 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0351014 Medline TA: Curr Med Res Opin Country: England |
Other Details:
|
Languages: eng Pagination: 843-50 Citation Subset: IM |
Affiliation:
|
Tibotec Therapeutics, Bridgewater, NJ 08869, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Anti-Bacterial Agents / pharmacology, therapeutic use* Ciprofloxacin / pharmacology, therapeutic use Community-Acquired Infections / drug therapy*, microbiology Cross Infection / drug therapy*, microbiology Drug Resistance, Microbial Humans Ofloxacin / pharmacology, therapeutic use* Pneumonia, Bacterial / drug therapy*, microbiology Pseudomonas Infections / complications* Pseudomonas aeruginosa / drug effects*, isolation & purification Risk Assessment Risk Factors Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Bacterial Agents; 82419-36-1/Ofloxacin; 85721-33-1/Ciprofloxacin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in predialysis chronic kid...
Next Document: Improving the global management of the neurogenic bladder patient: part II. Future treatment strateg...